ZYTOMICS is a holding company formed through the acquisition of three entities: Zytomed Systems, ZytoVision, and 42 LifeScience. In 2023, it further expanded its footprint with the acquisition of Diagomics in France. Headquartered in Berlin and Northern Germany, ZYTOMICS offers consumables for Immunohistochemistry (IHC) and In-Situ Hybridization (ISH). ZYTOMICS is a niche manufacturer and supplier of specialty antibodies and probes that complement the testing capabilities of the most commonly used instruments in the market. The group directly sells to pathology labs in DACH region and France and through distributors internationally.